Eosinophilic Gastroenteritis Drug Pipeline — PatSnap Eureka
Eosinophilic Gastroenteritis Drug Pipeline: IL-5, IL-13 & Eosinophil Depletion Beyond the Esophagus
No approved therapies exist specifically for non-esophageal EGIDs. Explore the emerging cytokine-directed and eosinophil-depletion strategies — from IL-5Rα blockade to CCR3 antagonism — now expanding into the broader GI compartment.
Therapeutic Modalities by Development Stage
Six modalities across approved, clinical, and preclinical stages — none yet approved specifically for EGE.
EGIDs Beyond the Esophagus: A Clinically Underserved Spectrum
Eosinophilic gastrointestinal disorders (EGIDs) — encompassing eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC) — are immune-mediated diseases characterized by pathological eosinophil accumulation throughout the GI tract beyond the esophagus. With no approved therapies specifically targeting non-esophageal EGIDs, the field is expanding cytokine-directed and eosinophil-depletion strategies from the esophageal arena into the broader gastrointestinal compartment.
As documented by the Tulane Eosinophilic Disorder Center, IL-4, IL-5, IL-13, IL-15, IL-18, eotaxin-1, eotaxin-2 and eotaxin-3 play a critical role in EGID pathogenesis, encompassing EoE, EG, EGE, and eosinophilic colitis. EGE is further classified by Klein's three anatomical subtypes — mucosal, muscular, and serosal — with clinical features including abdominal pain, diarrhea, ascites, and peripheral eosinophilia shaped by depth of bowel wall involvement.
The NIH and academic centers including leading research institutions have characterized TSLP pathway dysregulation in EGE: TSLP mRNA expression is significantly reduced in EGE gastric and small intestinal tissues compared with healthy controls, distinguishing non-esophageal disease from esophageal phenotypes and suggesting an upstream epithelial alarmin target shared with asthma biology.
The chemokine receptor CCR3 and its ligands (eotaxins) are highlighted in preclinical models as critical drivers of eosinophil trafficking into GI mucosa beyond the esophagus, representing a GI-specific target distinct from the IL-4/IL-13 pathway that dominates the current commercial IP landscape.
Seven Approaches Targeting Eosinophilic GI Disease
From approved biologics in adjacent indications to preclinical GI-specific models — the pipeline spans cytokine blockade, receptor antagonism, and small-molecule immunomodulation.
Dupilumab: Dual IL-4/IL-13 Blockade
Regeneron's dupilumab — FDA-approved for EoE in May 2022 — inhibits IL-4 and IL-13 signaling via anti-IL-4Rα. The shared Th2 molecular pathogenesis with non-esophageal EGIDs creates scientific rationale for extension to EGE and EG. A case report documented eosinophilic gastritis following dupilumab discontinuation, signaling biological target validation in gastric tissue. Regeneron holds at least 9 active patent filings (2016–2025) across IL and SG jurisdictions.
Approved (EoE) · Preclinical signals for EGEMepolizumab, Reslizumab & Benralizumab
IL-5 is the most extensively cited eosinophil-selective target. Anti-IL-5 antibodies (mepolizumab, reslizumab) prevent IL-5 from engaging its receptor; anti-IL-5Rα antibodies (benralizumab) additionally induce target-cell lysis via ADCC. A case report documented complete histological remission of EoE in a patient with comorbid severe asthma under benralizumab — clinical translational evidence for mucosal eosinophil depletion. IL-5 blockade also ameliorates chronic intestinal colitis in mouse models via the IL-23/GM-CSF axis.
Approved (asthma) · Case reports for EGIDsEotaxin Receptor Blockade in EGE
CCR3, the receptor for eotaxins-1/2/3, is a validated target for eosinophil trafficking specifically in non-esophageal GI tissue. In an OVA-sensitized mouse model of EGE, an anti-CCR3 monoclonal antibody significantly reduced intestinal mucosal eosinophilia, mucosal injury, and diarrhea severity compared to control IgG — one of the few non-esophageal EGID-specific experimental models in the retrieved dataset. No assignee in this dataset holds patents in this space for GI indications.
Preclinical (mouse model) · IP gap identifiedMontelukast & Second-Line Agents
Leukotriene D4 is implicated in GI eosinophil recruitment, providing mechanistic rationale analogous to its role in asthma. Case reports document successful montelukast use in EGE. A University of Iowa case report covers second-line therapies including mast cell stabilizers (cromolyn, ketotifen) and suplatast tosilate — a selective Th2 cytokine (IL-4 and IL-5) inhibitor — as steroid-sparing approaches for EGE management.
Clinical off-label · Case series evidenceTofacitinib & JAK-STAT6 Pathway
JAK-STAT6 pathway inhibitors block eotaxin-3 secretion by both esophageal epithelial cells and fibroblasts, addressing the fibrotic component of eosinophilic GI disease. A case report describes successful treatment of refractory EoE with tofacitinib (a JAK1/3 inhibitor) achieving histological improvement after 3 months. Eotaxin-3 is also directly regulated by the JAK-STAT6 pathway in GI stromal cells.
Case report · Preclinical for GI applicationSystemic Steroids & Oral Budesonide
Systemic corticosteroids (prednisone) remain the mainstay of EGE treatment. Oral budesonide in suspension and enteric-coated forms is described as effective with potentially improved GI distribution. The steroid-dependence of EGE and high relapse rate upon dose reduction underscores the critical unmet need for steroid-sparing biologics in this indication.
Standard of care (off-label) · High relapse rateKey Molecular Targets: Evidence Strength & Pipeline Positioning
Patent and literature signals from PatSnap Eureka, quantifying the relative evidence base for each molecular target in non-esophageal eosinophilic GI disease.
Molecular Target Evidence Strength in EGE Pipeline
IL-5/IL-5Rα leads with the broadest evidence base; CCR3 shows the strongest GI-specific preclinical proof-of-concept.
Evidence Source Split: Patent vs. Literature in EGID Dataset
Patent activity is predominantly commercial (Regeneron); EGE-specific non-esophageal science is predominantly academic-literature driven.
Key Targets: From IL-5 to AHR — What the Evidence Shows
Mechanistic signals from patent and literature records across six molecular targets relevant to eosinophilic gastroenteritis and pan-GI eosinophilic disease.
IL-5 / IL-5Rα: The Primary Eosinophil-Selective Target
IL-5 drives terminal differentiation of eosinophils from bone marrow progenitors and is the primary survival signal for tissue eosinophils. Anti-IL-5 or anti-IL-5Rα strategies deplete both circulating and mucosal eosinophils. Benralizumab's additional ADCC mechanism produces more complete depletion. The IL-33/ST2 axis activates ILC2s in bone marrow, driving IL-5-dependent eosinophilia — revealing upstream targets for future intervention.
IL-13 / IL-4Rα: Upstream Inducer & Approved Template
IL-13 is a key upstream inducer of esophageal and intestinal eosinophilia. IL-13 levels and eotaxin-3 are elevated in serum of EoE patients and are measurable biomarkers. Dupilumab's dual IL-4/IL-13 blockade via IL-4Rα is the only approved biologic strategy in EoE, providing the mechanistic template for non-esophageal extension. A post-hoc Phase II analysis confirmed dupilumab's gene expression modulation correlates with histological severity in EoE.
CCR3 / Eotaxins: GI-Specific Trafficking Control
The eotaxin-CCR3 axis controls eosinophil homing specifically to the GI mucosa. Anti-CCR3 monoclonal antibody preclinical data in EGE directly demonstrates that blocking this receptor reduces intestinal eosinophilic infiltration and tissue injury. Eotaxin-3 is also directly regulated by the JAK-STAT6 pathway in GI stromal cells. CCR3 antagonism represents an underexploited, GI-specific target with direct EGE preclinical proof-of-concept.
TSLP: Epithelial Alarmin Dysregulated in EGE
Abnormal TSLP isoform expression in EGE gastric and small intestinal mucosa distinguishes non-esophageal disease from controls, suggesting an upstream epithelial alarmin target shared with asthma biology. TSLP mRNA expression was significantly reduced in EGE tissues compared with healthy controls in a Nanjing Medical University study, pointing to dysregulation of epithelial alarmin signaling in stomach and small intestinal segments.
What the Clinical Record Shows for EGID Biologics
Retrieved results contain no data from prospective randomized controlled trials specifically targeting EGE, EG, or eosinophilic colitis with IL-5, IL-13, or IL-4Rα directed agents. The clinical evidence for non-esophageal EGID biologics is limited to case reports and retrospective cohorts — a significant gap that creates both regulatory opportunity and scientific urgency.
Dupilumab (FDA-approved, EoE): Phase III data show 300 mg weekly significantly improved signs and symptoms versus placebo. A post-hoc Phase II analysis correlates dupilumab-modulated gene expression with histological and endoscopic severity in EoE, providing a biomarker framework potentially applicable to non-esophageal disease. According to FDA records, this represented the first therapeutic approval for eosinophilic esophagitis.
Benralizumab (anti-IL-5Rα): A case report documents complete histological remission of EoE in a 56-year-old patient with comorbid severe asthma, achieved under benralizumab therapy initiated for asthma — clinical translational evidence that IL-5Rα blockade achieves mucosal eosinophil depletion, though prospective EGID trials are not documented in this dataset.
EGE Clinical Cohort (Mayo Clinic): A retrospective study of 35 EGE patients (2007–2018) characterized severe versus mild disease subtypes by weight loss, hypoalbuminemia, serosal involvement, and anemia. No biologics were described as standard treatment, confirming the unmet need. Explore the PatSnap Analytics platform for deeper cohort intelligence.
A case report also documents EGE diagnosis in a patient receiving golimumab (anti-TNF-α), with resolution under prednisolone — suggesting that non-selective immunosuppression may paradoxically unblock eosinophilic GI disease. For life sciences pipeline tracking, the PatSnap Life Sciences solution provides comprehensive drug development intelligence.
Combination Approaches & Next-Generation Strategies
Retrieved results signal five strategic directions beyond single-agent cytokine blockade, each addressing limitations of current monotherapy approaches in non-esophageal EGIDs.
Track emerging EGID combination strategies in real time
PatSnap Eureka monitors patent filings, clinical trial registrations, and literature across all EGID targets.
Who Is Driving the EGID Innovation Landscape?
Patent activity is predominantly commercial (Regeneron); EGE-specific non-esophageal science is predominantly academic-literature driven — indicating a gap between commercial IP focus and scientific understanding of pan-GI eosinophilic disease.
| Assignee / Institution | Evidence Type | Primary Focus | Jurisdiction / Stage |
|---|---|---|---|
| Regeneron Pharmaceuticals | Patent (9+ filings) | Anti-IL-4Rα (dupilumab) methods for EoE | IL, SG, BR · 2016–2025 |
| Boyce Thompson Institute | Patent (EP active) | Ascaroside (ascr#7) treatment of EoE | EP · Novel non-cytokine approach |
| Cincinnati Children's / U. Cincinnati | Literature | EoE transcriptomics, IL-13/IL-5 biology, diagnostic panels | Academic · Multiple papers |
| Université Libre de Bruxelles | Literature | IL-5 pathway review for non-asthma eosinophilic conditions incl. GI | Academic · Review paper |
| Korea University Anam Hospital | Literature | CCR3 preclinical EGE mouse model | Academic · Preclinical |
| Mayo Clinic | Literature | EGE clinical cohort characterization (35 patients, 2007–2018) | Academic · Retrospective |
| Nanjing Medical University | Literature | TSLP expression in EGE mucosal tissue | Academic · Translational |
| University of Oxford / Kennedy Institute | Literature | GM-CSF/IL-23/eosinophil axis in colitis | Academic · Preclinical |
Identify IP gaps before competitors do
Use PatSnap Analytics to map white-space in the CCR3 and IL-5 GI patent landscape.
Eosinophilic Gastroenteritis Drug Pipeline — key questions answered
IL-4, IL-5, IL-13, IL-15, IL-18, eotaxin-1, eotaxin-2 and eotaxin-3 play a critical role in EGID pathogenesis, encompassing eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis.
Dupilumab received FDA approval for eosinophilic esophagitis (EoE) in May 2022. In this dataset, no patents or prospective trial data extend this approved mechanism to EGE, EG, or eosinophilic colitis specifically. However, a case report documented eosinophilic gastritis diagnosed in a patient following dupilumab discontinuation, signaling biological relevance of this target in gastric tissue.
CCR3, the receptor for eotaxins-1/2/3, is a validated target for eosinophil trafficking specifically in non-esophageal GI tissue. In an OVA-sensitized mouse model of EGE, an anti-CCR3 monoclonal antibody significantly reduced intestinal mucosal eosinophilia, mucosal injury, and diarrhea severity compared to control IgG.
Systemic corticosteroids (prednisone) are the mainstay of EGE treatment, with oral budesonide (in suspension and enteric-coated forms) described as an effective steroid with potentially improved GI distribution. The steroid-dependence of EGE and high relapse rate upon dose reduction underscores the unmet need for steroid-sparing biologics.
A case report from the University of Gothenburg Hospital documented complete histological remission of eosinophilic esophagitis under benralizumab therapy for comorbid severe asthma, providing clinical translational evidence that IL-5Rα blockade achieves mucosal eosinophil depletion. Prospective EGID trials are not documented in this dataset.
Emerging targets include the aryl hydrocarbon receptor (AHR), which contributes to intestinal eosinophil homeostasis; the TSLP pathway, which shows abnormal expression in EGE gastric and small intestinal mucosa; the IL-33/ST2 axis activating ILC2s in bone marrow; and the GM-CSF/IL-23 axis operative in serosal-layer EGE and chronic intestinal colitis.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About EGEAccelerate Your EGID Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to map cytokine targets, identify IP gaps, and track the eosinophilic GI disease pipeline in real time.
References
- Tulane Eosinophilic Disorder Center — Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders (IL-4, IL-5, IL-13, IL-15, IL-18, eotaxin-1/2/3 in EGID pathogenesis)
- Eosinophilic gastroenteritis: Approach to diagnosis and management (Klein's anatomical subtypes; histological confirmation criteria)
- Nanjing Medical University — Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis
- Korea University Anam Hospital — CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis
- The Gene Expression Signature Modulated by Dupilumab is Correlated with Histological Severity and Endoscopic Features of Mucosal Inflammation and Remodelling in Eosinophilic Oesophagitis
- Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab (gastric tissue target validation following dupilumab discontinuation)
- Université Libre de Bruxelles — Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
- Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report (University of Gothenburg Hospital)
- University of Oxford / Kennedy Institute — Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis
- Eosinophilic gastroenteritis in a young girl – long term remission under Montelukast (leukotriene D4 receptor antagonism in EGE)
- University of Iowa — Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review (incl. suplatast tosilate)
- JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients
- Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib (JAK1/3 inhibitor case report)
- Eosinophilic gastroenteritis with gastric and small bowel involvement: successful treatment with oral budesonide
- Hokkaido — Successful Treatment of Eosinophilic Gastroenteritis with Clarithromycin (macrolide immunomodulation)
- First Therapeutic Approval for Eosinophilic Esophagitis (dupilumab FDA approval, May 2022)
- Mayo Clinic — Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course (35-patient retrospective cohort, 2007–2018)
- University of Colorado — Heterogeneity of Intestinal Tissue Eosinophils: Potential Considerations for Next-Generation Eosinophil-Targeting Strategies
- The aryl hydrocarbon receptor contributes to tissue adaptation of intestinal eosinophils in mice (AHR deficiency effects on GI eosinophil homeostasis)
- DBV Technologies — Epicutaneous Immunotherapy (EPIT) Blocks the Allergic Esophago-Gastro-Enteropathy Induced by Sustained Oral Exposure to Peanuts in Sensitized Mice
- Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist (golimumab-triggered EGE)
- National Institutes of Health (NIH) — Eosinophilic Gastrointestinal Disease Research Resources
- U.S. Food and Drug Administration (FDA) — Drug Approval Database (dupilumab EoE approval, May 2022)
- World Health Organization (WHO) — Rare and Immune-Mediated Disease Classification
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.